Alamandine abrogates neutrophil degranulation in atherosclerotic mice.

Analina R Da SilvaSébastien LengletFederico CarboneFabienne BurgerAline RothLuca LiberaleAldo BonaventuraFranco DallegriNikolaos StergiopulosRobson A S SantosFrançois MachRodrigo A Fraga-SilvaFabrizio Montecucco

Published in: European journal of clinical investigation (2017)

These results suggest that treatment with the MrgD agonist alamandine led to a reduced release of neutrophil granule products, potentially interfering with pro-atherosclerotic neutrophil activation.

Keyphrases

anti inflammatory
type diabetes
metabolic syndrome
adipose tissue
skeletal muscle
combination therapy
replacement therapy
smoking cessation